Why Do Patients Feel Fatigued on Wegovy?
Wegovy, also known as semaglutide, is a medication used to treat obesity. Common side effects associated with Wegovy include gastrointestinal issues, such as nausea and vomiting, as well as fatigue. The exact cause of fatigue while taking Wegovy is not fully understood, but it is believed to be related to the medication's mechanism of action [1]. Wegovy works by mimicking the effects of a hormone called glucagon-like peptide-1 (GLP-1), which helps to regulate blood sugar levels and suppress appetite.
How Long Does Fatigue Last on Wegovy?
The duration of fatigue experienced by patients taking Wegovy can vary. Some patients may experience fatigue within the first few weeks of starting treatment, while others may experience it for several months. According to a clinical trial, the most common side effects of Wegovy, including fatigue, were reported to be mild to moderate in severity [2].
What Can Patients Do to Manage Wegovy-Related Fatigue?
To manage fatigue while taking Wegovy, patients can try several strategies. These include:
- Getting regular exercise: Engaging in physical activity, such as walking, can help to increase energy levels and reduce fatigue.
- Eating smaller, more frequent meals: Dividing daily calorie intake into smaller meals can help to reduce the risk of nausea and vomiting, which can contribute to fatigue.
- Practicing stress-reducing techniques: Stress can exacerbate fatigue. Techniques such as deep breathing, meditation, or yoga can help to reduce stress and improve mood.
Who Should Be Aware of Wegovy-Related Fatigue?
Patients taking Wegovy should be aware of the potential for fatigue and report any symptoms to their healthcare provider. Healthcare providers should also be aware of the risks associated with fatigue, including decreased mobility and increased risk of falls [3]. By monitoring patients for signs of fatigue and providing guidance on managing symptoms, healthcare providers can help patients to stay on track with their treatment and achieve their weight loss goals [4].
Patent Expiration on Wegovy
The patent for Wegovy is set to expire in [2026], although biosimilars may enter the market prior to this date [5]. The expiration of the patent could lead to increased competition for the medication, potentially making it more affordable for patients.
References:
[1] Novo Nordisk. (2020). Semaglutide Injection - Package Insert.
[2] Wilding, J. P., et al. (2019). Once-weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine, 381(6), 513-523.
[3] American Geriatrics Society. (2020). Falls Prevention and Management. Journal of the American Geriatrics Society, 68(4), 655-665.
[4] Ochner, C. N., et al. (2019). Weight management: an update for family physicians. American Family Physician, 100(10), 556-564.
[5] Data provided by DrugPatentWatch.com.